Hematology and Oncology Book

http://www.fpnotebook.com/

Ximelagatran

Aka: Ximelagatran
  1. Background
    1. No longer available (off market in U.S.) due to hepatotoxicity
    2. Listed for historical reasons only
  2. Indications: Non-Valvular Atrial Fibrillation
    1. Warfarin intolerant
    2. Patients with high risk of Intracranial Hemorrhage
  3. Advantages
    1. As effective as Warfarin with INR 2-3
    2. Ximelagartan does not require monitoring
    3. Ximelagartan has fewer bleeding complications
  4. Disadvantages
    1. Expensive
    2. Myocardial Ischemia risk
    3. Risk of severe liver toxicity
  5. Dosing
    1. Studies used fixed dose of 36 mg bid
  6. References
    1. Albers (2005) JAMA 293:690-8
    2. Olsson (2003) Lancet 362:1691-8

ximelagatran (C0966370)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C426686
SnomedCT 415853004
English xi-melagatran, XIMELAGATRAN, ximelagatran [Chemical/Ingredient], Ximelagatran (substance), Ximelagratan, Ximelagratan (substance), Ximelagatran, glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, ximelagatran
Spanish ximelagatrán, ximelagatrán (sustancia), ximelagratan, ximelagratan (sustancia)
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree